Jasper Therapeutics (JSPR) News Today → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Free JSPR Stock Alerts $20.92 +0.16 (+0.77%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 3:15 PM | finanznachrichten.deJasper Therapeutics, Inc.: Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsMay 14 at 3:15 PM | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Stereotaxis (STXS), Jasper Therapeutics (JSPR)May 14 at 3:13 PM | investorplace.comJSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024May 14 at 8:00 AM | globenewswire.comJasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsMay 14 at 6:50 AM | americanbankingnews.comReviewing Neurocrine Biosciences (NASDAQ:NBIX) and Jasper Therapeutics (NASDAQ:JSPR)May 13 at 8:00 AM | globenewswire.comJasper Therapeutics Announces Briquilimab Development Program in AsthmaMay 11 at 5:41 PM | marketbeat.comMonaco Asset Management SAM Takes Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Monaco Asset Management SAM purchased a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 249,563 shares of the company's stock, valued at apprMay 9, 2024 | americanbankingnews.comJasper Therapeutics, Inc. Forecasted to Earn Q1 2024 Earnings of ($1.43) Per Share (NASDAQ:JSPR)May 8, 2024 | americanbankingnews.comHC Wainwright Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)May 7, 2024 | globenewswire.comJasper Therapeutics to Present at Upcoming Investor Conferences in MayMay 7, 2024 | markets.businessinsider.comBriquilimab’s Market Potential and Competitive Advantage in Autoimmune Diseases: An Investment OpportunityMay 7, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Jasper Therapeutics (JSPR) with Buy RecommendationMay 6, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at HC WainwrightHC Wainwright assumed coverage on shares of Jasper Therapeutics in a research report on Monday. They set a "buy" rating and a $65.00 price target on the stock.May 4, 2024 | morningstar.comJasper Therapeutics Inc Ordinary SharesApril 29, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Position Raised by Fernwood Investment Management LLCFernwood Investment Management LLC increased its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 8.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor ownApril 25, 2024 | markets.businessinsider.comBuy Rating Affirmed: Jasper Therapeutics’ Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment MarketApril 3, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at Evercore ISIEvercore ISI assumed coverage on Jasper Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $65.00 price objective on the stock.April 2, 2024 | globenewswire.comJasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Buy" from AnalystsShares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have received an average recommendation of "Buy" from the seven research firms that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The aMarch 28, 2024 | msn.comRBC starts Jasper Therapeutics at outperform, cites market opportunityMarch 28, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Receives New Coverage from Analysts at Royal Bank of CanadaRoyal Bank of Canada began coverage on shares of Jasper Therapeutics in a report on Thursday. They set an "outperform" rating and a $70.00 price target for the company.March 21, 2024 | globenewswire.comJasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria TreatmentMarch 20, 2024 | finance.yahoo.comJasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders are retail investors with 42% ownership, institutions own 26%March 19, 2024 | globenewswire.comJasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible UrticariaMarch 18, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Earns Outperform Rating from Analysts at TD CowenTD Cowen assumed coverage on shares of Jasper Therapeutics in a research report on Monday. They issued an "outperform" rating for the company.March 16, 2024 | finance.yahoo.comJSPR Jul 2024 40.000 callMarch 15, 2024 | finanznachrichten.deJasper Therapeutics, Inc.: New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi AnemiaMarch 15, 2024 | globenewswire.comNew Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi AnemiaMarch 14, 2024 | msn.comEntrada Therapeutics GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85MMarch 13, 2024 | insidertrades.comJeetinder Singh Mahal Sells 900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) StockMarch 12, 2024 | marketbeat.comInsider Selling: Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells 900 Shares of StockJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) COO Jeetinder Singh Mahal sold 900 shares of Jasper Therapeutics stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $26.44, for a total transaction of $23,796.00. Following the transaction, the chief operating officer now directly owns 25,009 shares in the company, valued at $661,237.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 11, 2024 | finance.yahoo.comJSPR Oct 2024 30.000 callMarch 10, 2024 | finance.yahoo.comJSPR Oct 2024 17.500 callMarch 10, 2024 | finance.yahoo.comJSPR Apr 2024 35.000 callMarch 7, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been given a consensus rating of "Buy" by the six research firms that are covering the company, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issMarch 7, 2024 | marketbeat.comOppenheimer Reiterates "Outperform" Rating for Jasper Therapeutics (NASDAQ:JSPR)Oppenheimer restated an "outperform" rating and set a $80.00 target price on shares of Jasper Therapeutics in a report on Thursday.March 7, 2024 | marketbeat.comJasper Therapeutics, Inc. to Post Q1 2024 Earnings of ($1.19) Per Share, Capital One Financial Forecasts (NASDAQ:JSPR)Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at Capital One Financial lifted their Q1 2024 earnings estimates for Jasper Therapeutics in a research report issued to clients and investors on Monday, March 4th. Capital One Financial analyst T. Chiang now anticipates that tMarch 6, 2024 | finance.yahoo.comJSPR Mar 2024 22.500 putMarch 6, 2024 | investorplace.comJSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023March 6, 2024 | marketbeat.comWilliam Blair Weighs in on Jasper Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:JSPR)Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities researchers at William Blair upped their Q1 2024 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report released on Monday, March 4th. William Blair analyst M. Phipps now expects that the company will earnMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Jasper Therapeutics’ Progress and Potential in Addressing Unmet Needs in Chronic Urticaria TreatmentMarch 4, 2024 | finanznachrichten.deJasper Therapeutics, Inc.: Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comJasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate DevelopmentsMarch 3, 2024 | finance.yahoo.comJSPR Mar 2024 15.000 putFebruary 27, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)February 27, 2024 | markets.businessinsider.comBuy Rating on Jasper Therapeutics Highlighting Briquilimab’s Potential in Chronic Urticaria TreatmentFebruary 26, 2024 | globenewswire.comJasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare ConferenceFebruary 23, 2024 | globenewswire.comJasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingFebruary 23, 2024 | marketbeat.comCapital One Financial Weighs in on Jasper Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:JSPR)Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities researchers at Capital One Financial lowered their FY2023 EPS estimates for Jasper Therapeutics in a report issued on Wednesday, February 21st. Capital One Financial analyst T. Chiang now anticipates that the company will post earni Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. JSPR Media Mentions By Week JSPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼0.790.57▲Average Medical News Sentiment JSPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼142▲JSPR Articles Average Week Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DocGo News Anavex Life Sciences News Caribou Biosciences News MeiraGTx News SOPHiA GENETICS News Tenaya Therapeutics News Candel Therapeutics News Black Diamond Therapeutics News Invivyd News Adaptimmune Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCrypto Millionaire Says: “Buy This $11 AI Coin.”InvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperThe only AI company you should be looking atBehind the MarketsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
